Microfluidic System for Transplantation of Mitochondria in Immune Effector Cells

Abstract

Methods and systems are provided for analyzing the ability of immune cells to kill target cells based on the effectiveness of mitochondria of the immune cells. The systems and methods further can be used for transplanting healthy mitochondria into immune cells to increase their effectiveness against target cells. The methods described herein can be used in treatment of cancer, mitochondrial diseases, and certain metabolic diseases.

Claims

1. A method for analyzing a function of immune effector cells, the method comprising the steps of: (a) co-encapsulating a first immune effector cell with a first target cell in an aqueous microdroplet and encapsulating a second immune effector cell with a second target cell in another aqueous microdroplet using a microfluidic device; (b) incubating the co-encapsulated cells for a period of time in the microfluidic device and observing interaction between the immune effector cells and the target cells, wherein the first immune effector cell is observed to interact more effectively with the first target cell than the second immune effector cell interacts with the second target cell; (c) isolating the first immune effector cell and the second immune effector cell; (d) extracting one or more mitochondria from the first immune effector cell and from the second immune effector cell and sequencing mitochondrial DNA from the extracted mitochondria obtained from the first and second immune effector cells; and (e) comparing the mitochondrial DNA sequences obtained from the first and second immune effector cells, thereby identifying differences in mitochondrial DNA sequence potentially related to a function of the immune effector cells.

2. The method of claim 1, further comprising: (d1) sequencing genomic DNA and/or mRNA from the first immune effector cell and from the second immune effector cell; and (e1) comparing the genomic DNA and/or mRNA sequences obtained from the first and second immune effector cells, thereby identifying differences in genomic DNA sequences and/or mRNA sequences potentially related to a function of the immune effector cells.

3. The method of claim 1, wherein a genetic deficiency is identified in the mitochondrial DNA of the second immune effector cell, which genetic deficiency is not present in the mitochondrial DNA of the first immune effector cell.

4. The method of claim 2, wherein a genetic deficiency is identified in the genomic DNA and/or mRNA of the second immune effector cell, which genetic deficiency is not present in the genomic DNA and/or mRNA of the first immune effector cell.

5. The method of claim 1, wherein step (c) comprises separating the first and second immune effector cells using a droplet sorter that separates microdroplets based on an indicator of effectiveness of interactions between an immune effector cell and a target cell.

6. A method of enhancing a function of immune effector cells by mitochondrial transplantation, the method comprising the steps of: (a) performing the method of claim 1 on one or more pairs of first and second immune effector cells to identify differences in mitochondrial DNA sequences or differences in genomic DNA or mRNA sequences between said first and second immune effector cells of each pair; (b) selecting one or more donor cells for mitochondrial transplantation from said one or more pairs of first and second immune effector cells based on said mitochondrial DNA sequences, or said genomic DNA or mRNA sequences, or said identified differences; (c) selecting one or more recipient cells for mitochondrial transplantation from said one or more pairs of first and second immune effector cells based on said mitochondrial DNA sequences, or said genomic DNA or mRNA sequences, or said identified differences; and (d) extracting mitochondria from the one or more selected donor cells and transplanting the extracted mitochondria into the one or more selected recipient cells to obtain one or more immune transplant cells.

7. The method of claim 6 further comprising, in step (d), editing one or more sequences of mtDNA in the mitochondria for transplantation prior to said transplanting.

8. The method of claim 6 further comprising, in step (d), editing one or more sequences of genomic DNA in the second immune effector cell prior to said transplanting.

9. The method of claim 6, wherein a function of one or more recipient cells is enhanced.

10. The method of claim 9, wherein the enhanced function is ability to kill target cells, increased rate of killing of target cells, and/or increased incidence of serial killing of target cells by one or more recipient cells.

11. The method of claim 6, further comprising culturing and expanding the immune transplant cell to form a plurality of progeny of the immune transplant cell in a culture medium.

12. The method of claim 6, wherein any of the first immune effector cell, the second immune effector cell, and the immune transplant cell are selected from the group consisting of T cells, NK cells, CAR T cells, neutrophils, monocytes, and macrophages.

13. The method of claim 6, wherein the target cell is selected from the group consisting of tumor cells, microbial cells, bacteria, and virus-infected cells.

14. The method of claim 6, wherein the first and second immune effector cells are obtained or derived from one individual.

15. The method of claim 6, wherein the first and second immune effector cells are obtained or derived from different individuals.

16. The method of claim 15, wherein the different individuals are humans or non-human mammals.

17. A method for transplanting mitochondria into an immune effector cell, the method comprising the steps of: (a) providing (i) a microfluidic device configured for co-encapsulating cells in aqueous microdroplets in an oil stream, (ii) a suspension of immune effector cells, and (iii) a suspension of donor mitochondria; (b) producing a plurality of aqueous microdroplets from the suspension of immune effector cells and the suspension of mitochondria using the microfluidic device, wherein the plurality of aqueous microdroplets comprises microdroplets comprising both one or more effector cells and one or more donor mitochondria; (c) incubating the aqueous microdroplets, whereby donor mitochondria are taken up into immune effector cells to form immune transplant cells; and (d) collecting the immune transplant cells; wherein the immune effector cells provided in (a) are known to possess a genetic deficiency in their mitochondria, and wherein the donor mitochondria provided in (a) are known to not possess said genetic deficiency.

18. The method of claim 17, further comprising sequencing mitochondrial DNA of the immune effector cells and/or the donor mitochondria and analyzing the resulting sequences to identify a presence or absence of potential genetic defects.

19. The method of claim 17, further comprising culturing and expanding the collected immune transplant cells to form a plurality of progeny of the immune transplant cells in a culture medium.

20. A method to aid in treating a cancer, a mitochondrial disease, or a metabolic disease, in a subject in need thereof, the method comprising performing the method of claim 6, wherein the immune effector cells are obtained or derived from the subject.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0023] FIG. 1 shows a schematic representation of a general workflow of a mitochondria transplantation process. The process can be used, for example, to improve the toxicity of effector cells for cancer immunotherapy.

[0024] FIG. 2 shows a schematic representation of a workflow for immune cell mitochondrial transplantation using a microfluidic device and aqueous microdroplet sorter device.

[0025] FIG. 3 is a schematic representation of a microfluidic device for mitochondrial transplantation of single cells.

DETAILED DESCRIPTION

[0026] The present technology utilizes microfluidic single-cell technology to co-encapsulate immune cells and target cells in aqueous microdroplets in an oil stream. This system makes it possible to view various parameters of interest, including cytotoxicity, the immune killing of target cells, and drug potency for drug conditional studies..sup.18,19 The system allows characterization of dynamic functional responses of single cells and their interactions in real time, for example, when a target tumor cell and an immune effector cell are in the same microenvironment, such as co-localized in an aqueous microdroplet. The methods described herein can be used in particular to analyze and alter effector cell mitochondrial function and makeup using single cell resolution, droplet sorting by a specially adapted droplet sorter device, followed by transcriptomic, proteomic, and epigenomic analysis, including mass spectrometry characterization, to unlock and repair genetic drivers of immune cell regulation and action.

[0027] The technology utilizes a microfluidics-based single cell sorting device to co-encapsulate immune cells and target cells in aqueous microdroplets in an oil stream. The device allows the user to evaluate various parameters of interest in the encapsulated cells, including parameters such as cytotoxicity, immune cell killing of target cells, drug potency, and more. In this system, the following steps can be performed to carry out transplantation of mitochondria from one immune cell to another.

[0028] The technology can be used to isolate and transplant mitochondria based on any of several specific cell functions that depend on mitochondrial function. For example, mitochondria can be transplanted from drug-sensitive cells or highly functional immune effector cells to drug-resistant cells or functionally impaired immune effector cells, which can increase functionality of an immune response or drug/chemo-sensitivity in cells with newly implanted exogenous mitochondria, and progeny of such cells. This technology can be used in conjunction with an immunotherapy.

[0029] A variety of technologies (single cell sorting devices) are available to perform sorting in a microfluidic device of microdroplets containing cells of interest. Known technologies and even commercial kits are available for mitochondrial isolation from cells.

[0030] The present technology can access the functional activity of individual effector cells and, where that activity is related to mitochondria of the cells, transfer the mitochondria to other cells with useful properties (e.g., target specificity) but lacking in effectiveness due to defective or poorly functioning mitochondria. The technology also enables genomic analysis of mitochondrial subpopulations that are correlated with the function of specific single cells. The technology allows selection of mitochondria based on the functionality of cell types and sorting of cells with highly functional mitochondria. Selected mitochondria can be isolated and transplanted into cells in order to modulate immune cell activity or functionality based on the introduction of exogenous mitochondria.

[0031] The technology can be used with a variety of immune effector cells, either from the same individual donor (autologous) or different donors (heterologous), including natural killer (NK) cells, cells expressing a chimeric antigen receptor (CAR) (e.g., CAR T cells), or other T cells. Cells receiving a mitochondrial transplant can then be propagated and introduced into an individual patient (autologous or heterologous treatment) for enhancing a cell function in the patient, such as to provide more efficient killing of cancer cells or pathogens in the patient.

[0032] A five step protocol for carrying out cell and mitochondrial selection and transplantation using a single-cell-based microfluidic system is summarized in FIG. 1. The five steps of this protocol are described below.

[0033] Step (1). Co-encapsulate an immune cell with a target cell in an aqueous microdroplet using a microfluidic device.

[0034] Step (2). Incubate the co-encapsulated cells for a period of time, such as about 6 hours, to allow observation and characterization of function of the immune cell. Light microscopy and optionally fluorescence are used to observe and characterize the actions of the immune cell, including interactions between the immune cell and the target cell.

[0035] Step (3). Separate and isolate proven killers (immune effector cells observed to have killed target cells, e.g., tumor cells) from nonkillers (immune effector cells that have not killed target cells, such as where the target cell remains alive during the incubation) using a sorter module of the microfluidic device.

[0036] Step (4). Extract mitochondria from one or more isolated proven killer cells and transplant them into one or more isolated proven nonkiller cells.

[0037] Step (5). Incubate the nonkiller cells that have received transplanted mitochondria with one or more target cells and observe whether the nonkiller cells that received transplanted mitochondria have improved killing ability with respect to the target cells.

[0038] An optional additional step (Step (6)) includes sequencing the mitochondrial genome of both nonkiller and killer effector cells to assess the differences in the mitochondrial genome associated with cytotoxic activity or other cell functions.

[0039] Mitochondrial transplantation involves the delivery of healthy or functional mitochondria into a region of damage..sup.20,21 The spontaneous uptake of functional mitochondria by damaged cells occurs through endocytosis and allows for cell healing and repair of reversible damage..sup.15,21,22 Mitochondrial transfer into damaged or dysfunctional NK cells will improve NK function in populations of NK cells having deficiencies in mitochondrial function. Mitochondrial transplantation at the single-cell level also can provide information about individual NK cells before and after replenishing their mitochondrial population.

[0040] In the present technology, autologous or heterologous NK cells or T cells can be obtained from a suitable donor using known methods. After observation in a microfluidic device having a docking array for aqueous microdroplets, the cells can be classified based on function, separating active and/or serial killer cells from less effective or ineffective killer cells using a droplet sorter. Subsequently, mitochondria can be isolated from the active and/or serial killer cells, and then transplanted into ineffective or poorly effective (i.e., nonkiller) cells to determine whether the transferal of a mitochondrial subpopulation affects the phenotype of nonkiller cells.

[0041] Many different cell types can be characterized and used for mitochondrial transplantation, either as mitochondrial donors or acceptors, using the present technology. These include immune effector cells, such as natural killer cells, CAR T cells, other T cells, neutrophils, monocytes, and macrophages, as well as tumor cells other types of cells. Any type of cell can be characterized and used for mitochondrial transplantation as long as the cell type can be obtained as single cells suitable for introduction into aqueous microdroplets in a microfluidic device. Of particular interest are cells that interact with, and can be co-encapsulated with, other cells in aqueous microdroplets, and cells that have significant energy utilization rates and for which mitochondrial metabolism can be limiting for cellular function.

[0042] Mitochondria for transplantation and/or analysis can be obtained from (i.e, isolated from or extracted from) donor cells using a commercial kit. See, e.g., Sun et al., 2022, and kits from Beyotime (Kit C3601) and ThermoFisher (Kit 89801). Briefly, donor cells can be stained using Mito Tracker Green FM (Invitrogen, M7514), the donor cells lysed and homogenized, and the mitochondria isolated by differential centrifugation. For transplantation, the isolated mitochondria, suspended in an aqueous buffer solution, are co-encapsulated with recipient cells in aqueous microdroplets in a microfluidic device. The donor mitochondria are spontaneously taken up by endocytosis into the recipient cells. A variety of assays are available for use to test the effectiveness of mitochondrial transplantation. For example, if the recipient cells are NK cells, whose effectiveness at target cell killing is to be tested after mitochondrial transplantation, then staining of the target cells with propidium iodide (Invitrogen, P3566), a cell death marker, can be used to quantify the level of cell death obtained following co-encapsulation and incubation in aqueous microdroplets in oil in a microfluidic device.

[0043] Sequencing of mitochondrial DNA, genomic DNA, or mRNA can be by any known method, and can optionally include any desired type of amplification of the nucleic acid prior to sequencing. Differences in obtained sequences can be identified by any known method, and identified differences can be of any type, including insertions of any length, deletions of any length, inversions, point mutations, frame shift mutations, and the like. Identified sequence differences, or their association with a disease or genetic deficiency, can involve a single gene or multiple genes, and their location on a mitochondrial or cellular genome or within a genome, transcriptome, or proteome can be established using any known software, database, or algorithm. Genetic defects in mitochondria can be of any known type, such as, by non-limiting example, reduction or complete loss of an enzyme function or a metabolic pathway, reduction or complete loss of energy production by oxidative phosphorylation or lipid oxidation, or loss of structural integrity or ability of mitochondria to grow, proliferate, or migrate within a cell, or to be exchanged with other cells. Genetic defects in a cellular genome, i.e., in nuclear DNA or manifested in mRNA or gene expression or regulation, can be of any type that interacts with mitochondrial function directly or indirectly or other cellular functions, especially functions related to the roles of immune effector cells, such as production of cytokines, toxins, or free radicals, exocytosis, proliferation, antigen recognition, or signal transduction. Enhancement of any such functions, particularly if found as defective, can result in enhancement of an immune cell function or an immune function of a subject. Editing of mitochondrial or genomic DNA can be performed by any known method, including as nonlimiting examples through the use of CRISPR or the use of viral vectors or plasmids.

[0044] Microfluidic devices capable of co-encapsulating different cell types in microdroplets, or co-encapsulating cells with donor mitochondria in microdroplets, incubating large numbers of cell pairs or groups simultaneously in microdroplet arrays and analyzing their interactions by microscopy, as well as sorting and collection of microdroplets based on cell fluorescence, are known and described, for example, in WO 2018/013726 A1, U.S. Pat. No. 10,718,763 B2, WO 2020/023685 A1, WO 2020/223578 A1, WO 2020/247313 A1, US 2021/0260576 A1, and WO 2023/215608 A1, each of which is hereby incorporated by reference in its entirety.

[0045] The present technology provides several novel and advantageous features. It allows determination of the potency of immune cell immunogenicity within a population of immune cells based on mitochondrial makeup of the population. It also permits identification and sorting of highly active immune killer cells from less active immune killer cells. Further, the technology allows the preparation of a population of immune cells, or single cells, having increased immune killing activity at the single-cell level using mitochondrial transplantation. The technology provides methods for identifying mitochondrial subpopulations that differ in their support of immune killer activity, and for determining the underlying features of mitochondrial DNA, including mutations, that underlie functional deficiencies of several types of immune cells. The methods can be used, together with mitochondrial transplantation, to overcome CAR T cell exhaustion in cancer therapy. The methods of the present technology can also be used for profiling of immune cells of individual patients to study the capacity and functionality of the mitochondria of those immune cells. Yet another use of the technology is to perform mitochondrial therapy for patients with immune or metabolic diseases.

EXAMPLES

Example 1. Mitochondrial Isolation and Auto-Transplantation Efficacy

[0046] A commercially available mitochondria isolation kit is used for tissue and cell lysates (ThermoFisher, 89801) to harvest mitochondria from donor K562 leukemia cells. To visualize mitochondrial uptake through microscopy, SKOV-3 ovarian adenocarcinoma cells are stained with CellMask Deep Red (Invitrogen, C10046) and mitochondria from donor K562 cells are stained with Mito Tracker Green FM (Invitrogen, M7514). Using the aqueous microdroplet-based microfluidic device depicted in FIG. 3 with an oil injection inlet and two aqueous injection inlets, donor mitochondria and the recipient SKOV-3 cells are introduced through the two aqueous inlets and co-encapsulated into aqueous microdroplets in an oil stream. The cells and mitochondria are co-encapsulated in the droplets for 2 hours at 37 C. to allow for maximal mitochondrial uptake via endocytosis. Following the incubation period, the uptake of donor mitochondria into SKOV-3 cells is confirmed by microscopy. The droplets are then collected and cocultured with NK92 cells, and a plate-based assay is used to assess the sensitivity levels of SKOV-3 transplant cells to NK92 cytotoxicity.

Example 2. Sensitivity of SKOV-3 to NK92 Killing after Mitochondrial Transplantation into SKOV-3 Cells

[0047] The following experiment is designed to determine whether SKOV-3 cells become more susceptible to NK92 cytotoxicity after transplantation with sensitive mitochondria isolated from K562 cells. Tumor progression requires a substantial energy supply and tumor cells possess the ability to reprogram mitochondria for their own benefit. During tumor development mitochondria undergo an altered metabolism which may lead to an inactive cell death pathway. Through these alterations, tumor cells are able to evade apoptosis and immune surveillance contributing to their unconstrained proliferation and metastasis..sup.23

[0048] Mitochondrial transplantation is performed using a spiral microfluidic device (FIG. 3) for high throughput mitochondrial uptake through the increase of single-cell co-encapsulation ratio. The donor mitochondria are harvested from K562 cells. This tumor cell line has been proven to be highly susceptible to NK92 cytotoxicity..sup.24 The recipient cell, SKOV-3, a well-established human epithelial ovarian cancer cell line first derived from ovarian adenocarcinoma, has been found to be highly resistant to cytotoxic drugs..sup.25 NK92 cells are interleukin-dependent NK cells and have been rigorously used for immune cell studies for inducing cell mediated.

[0049] A plate-based LDH Coculture Assay is to test susceptibility of target tumor cells to NK92 cytotoxicity. A statistically significant difference in sensitivity to NK92 cytotoxicity between the target tumor cells is evidence that mitochondrial transfer can induce a distinct shift in tumor phenotypic response upon re-exposure to immune cell cytotoxicity. After a 2-hour coculture of SKOV-3 with NK92 cells in microdroplets, SKOV-3 cell viability is measured. Cells are recovered from droplets and stained with propidium iodide (Invitrogen, P3566), a cell death marker, to quantify the level of cell death following mitochondrial transplantation.

Example 3. Detection of a Mitochondrial Subpopulation in Tumors that Drive Tumor Proliferation and Metastasis

[0050] Tumor cells have been shown to hijack mitochondria for their own energy needs, using mitochondrial oxidative phosphorylation to promote tumor proliferation and expansion to other cellular environments. Tumor cells can also evade mitochondrially-engineered cell death (apoptosis) through various processes..sup.8 Here, tumor cells are transplanted with sensitive mitochondria (mitochondria with an intact cell death pathway). The sensitivity of the tumor cells to NK-induced killing and drug-induced apoptosis is measured following transplantation of mitochondria into the tumor cells.

Example 4. Asessment of the Role of Mitochondrial Metabolism in NK Cell Aging, Functionality, and Cytotoxicity Towards Target Cells

[0051] Using a microfluidic device with an integrated sorter module, serial killing NK cells are separated from less active NK cells based on an increased florescence signal that is produced when a target tumor cell is killed. Less active NK cells are used for auto-transplantation with mitochondria from highly active NK cells. Individual NK cells are analyzed for their killing ability before and after mitochondrial transplantation to determine if a particular cell's response is based on function of a mitochondrial subpopulation. Overall, droplet microfluidics can help us elucidate the role of NK and T cell metabolism in cancer development through single-cell isolation of immune cells that exogenous functional mitochondria have modified. The profiling of immune cells using this approach in patients can increase the efficacy of mitochondrial therapy as a high throughput method of treatment for patients with cancer, as well as mitochondrial and other metabolic diseases.

[0052] Aqueous microdroplets are generated with co-encapsulated NK92 immune cells and K562 tumor target cells. The droplets are incubated for 6 hours at 37 C to facilitate killing events (single cell killing, serial killing, and synaptic contact). Target tumor cell death is determined based on a standard apoptosis cell dye. Tumor cells are stained with CellEvent Caspase 3/7 apoptosis dye (Invitrogen, C10423) to detect killing events. Following incubation, a droplet sorter device is used to sort droplets into active (fast, serial killing) NK cells and inactive NK cells based on their killing ability for K562 tumor cells as target cells. When an active or serial NK cell kills a k562 that has been stained with an apoptosis dye, a fluorescent signal is produced which activates the sorter to direct the droplets containing active NK cells to a collection channel. The non-sorted droplets which contain inactive or non-killing NKs are collected in a separate waste channel. Both sets of droplets are collected for downstream processing. The isolated fast or serial killing NKs are recovered from droplets and expanded in culture. An LDH coculture assay is then carried out on sorted NK killer cells to establish whether expanded killer NK cells possess higher cytotoxicity compared to a heterogenous population of NK92 cells. the LDH coculture assay is repeated on expanded killer cells (after at least 2 weeks) to establish whether the expanded cells have approximately the same cytotoxicity as the originally sorted killer cells. Extracted mitochondria from the sorted and the later expanded killer NK cells are transplanted into inactive NK cells. These new NK transplant cells are then cocultured with target tumor cells in a microdroplet array device to determine if the killing ability of transplant cells has improved.

Example 5. Determination of Functional Interactomics of Potent Killer T Cells

[0053] Transcriptomics analysis using RNA sequencing is performed to determine what transcription factors are upregulated along specific pathways during an immune response by individual highly effective killer cells. Proteomics is also performed using mass spectrometry of the same cells to determine the most active proteins at the point of immune activation. Epigenetic analysis also is performed to determine changes in gene activity upon immune cell activation and killing. Biomarkers for the most effective killer cells are identified.

Example 6. Genetic Analysis of Highly Potent Killer T Cells

[0054] Mitochondria are crucial for regulating various intracellular signaling pathways and metabolic processes essential for NK cell activation, proliferation, and effector functions, such as cytokine production and cytotoxicity. (Klein, K.; He, K.; Younes, A. I.; Barsoumian, H. B.; Chen, D.; Ozgen, T.; Mosaffa, S.; Patel, R. R.; Gu, M.; Novaes, J. et al. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol 2020, 11, 573326). Mitochondrial DNA (mtDNA) plays a pivotal role in cellular metabolism and energy production. (Lei, T.; Rui, Y.; Xiaoshuang, Z.; Jinglan, Z.; Jihong, Z. Mitochondria transcription and cancer. Cell Death Discov 2024, 10 (1), 168; and Osellame, L. D.; Blacker, T. S.; Duchen, M. R. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab 2012, 26 (6), 711). While nuclear DNA contains the bulk of our genetic information, mtDNA specifically encodes vital components of the mitochondrial respiratory chain and is responsible for ATP generation. (Sharma, P.; Sampath, H. Mitochondrial DNA Integrity: Role in Health and Disease. Cells 2019, 8 (2)). Variations or mutations in mtDNA can impact mitochondrial function and cellular metabolism, potentially influencing NK cell activity and effectiveness. For example, mtDNA mutations can induce mitochondrial dysfunction, affecting ATP synthesis and cellular respiration, potentially impairing NK cell function.

[0055] In this example, the impact of mtDNA on NK antitumor activity is investigated. Specifically, differences exhibited by active killer cells in their mtDNA quantity and quality compared to NK cells that are less efficient in tumor cell eradication are determined. A microfluidics-and fluorescence-based sorting system is used to separate NK cell population into more homogeneous subpopulations based on their exhibited functional phenotype against a co-encapsulated target tumor cell within droplets.

[0056] Aqueous microdroplets are generated with co-encapsulated NK92 immune cells and K562 tumor target cells, and the droplets are incubated for 16 hours at 37 C to facilitate killing events (single cell killing, serial killing, and synaptic contact). Target tumor cell death is determined based on the uptake of CellEvent Caspase 3/7 apoptosis dye (Invitrogen, C10423), which is added to the tumor cell sample. Using a fluorescence-based droplet sorting platform, droplets are sorted into active (fast, serial killing) NK cells and inactive NK cells based on their cytotoxicity towards K562 tumor cells. When an active or serial killer NK cell kills a K562 cell that has taken up the apoptosis dye, a fluorescence signal is produced which activates the sorter to direct the droplets containing active NK cells to a collection channel. The non-sorted droplets, which contain lazy NK cells with live tumor cells, are collected in a separate waste channel. All droplets from both the collection and waste channels will be collected for downstream processing. Fluorescence signals are identified using a 488 nm laser (Opto Engine LLC, Midvale, UT) for excitation, coupled with a PMT (Hamamatsu Photonics, Hamamatsu City, Japan). Control and sorting of signal impulses are managed by a control unit and LabView software (National Instruments, Woburn, MA). The electronic signal sent to the device is subsequently amplified using a Trek 609C-6 High Voltage Amplifier (Advanced Energy, Denver, CO). At the beginning of each experiment, a baseline threshold for sorting is established, triggering an impulse upon detection of any fluorescence peak surpassing the baseline or background noise level.

[0057] Both the isolated active/serial killing and inactive/lazy NKs are recovered from droplets post sort and expanded in culture. Once the cell populations have been adequately expanded, mtDNA is extracted from both groups of cells and sequenced. Additionally, nuclear (i.e., genomic) DNA and mRNA are extracted from both sets of cells. Comparison of the sequences reveals disparities in genomic DNA and mtDNA within each NK cell population. Transcriptomic and genomic profiles are compared by isolating mRNA and nuclear DNA using standard isolation protocols immediately after cell sorting, while mtDNA extraction is conducted following cell sorting and subsequent cell expansion.

[0058] As used herein, consisting essentially of allows the inclusion of materials or steps that do not materially affect the basic and novel characteristics of the claim. Any recitation herein of the term comprising, particularly in a description of components of a composition or in a description of elements of a device, can be exchanged with consisting essentially of or consisting of.

[0059] While the present invention has been described in conjunction with certain preferred embodiments, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein.

REFERENCES

[0060] (1) Klein, K.; He, K.; Younes, A. I.; Barsoumian, H. B.; Chen, D.; Ozgen, T.; Mosaffa, S.; Patel, R. R.; Gu, M.; Novaes, J.et al. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol 2020, 11, 573326. [0061] (2) Brand, M. D.; Orr, A. L.; Perevoshchikova, I. V.; Quinlan, C. L. The role of mitochondrial function and cellular bioenergetics in ageing and disease. Br J Dermatol 2013, 169 Suppl 2 (0 2), 1. [0062] (3) Chen, W.; Zhao, H.; Li, Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther 2023, 8 (1), 333. [0063] (4) Weinberg, S. E.; Sena, L. A.; Chandel, N. S. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015, 42 (3), 406. [0064] (5) Song, Y.; Zhou, Y.; Zhou, X. The role of mitophagy in innate immune responses triggered by mitochondrial stress. Cell Commun Signal 2020, 18 (1), 186. [0065] (6) Bahat, A., MacVicar, T., & Langer, T. Metabolism and Innate Immunity Meet at the Mitochondria. Frontiers in Cell and Developmental Biology 2021, 9, 720490. [0066] (7) Chen, Y.; Zhou, Z.; Min, W. Mitochondria, Oxidative Stress and Innate Immunity. Front Physiol 2018, 9, 1487. [0067] (8) Warburg, O. On the origin of cancer cells. Science 1956, 123 (3191), 309. [0068] (9) Li, X. Y.; Fang, P.; Mai, J. T.; Choi, E. T.; Wang, H.; Yang, X. F. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. Journal of Hematology & Oncology 2013, 6. [0069] (10) Taylor, R. W.; Turnbull, D. M. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005, 6 (5), 389. [0070] (11) Smith, A. L. M.; Whitehall, J. C.; Greaves, L. C. Mitochondrial DNA mutations in ageing and cancer. Mol Oncol 2022, 16 (18), 3276. [0071] (12) Porporato, P. E.; Filigheddu, N.; Pedro, J. M. B.; Kroemer, G.; Galluzzi, L. Mitochondrial metabolism and cancer. Cell Res 2018, 28 (3), 265. [0072] (13) Wang, S. F.; Tseng, L. M.; Lee, H. C. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci 2023, 30 (1), 61. [0073] (14) Terren, I.; Orrantia, A.; Vitalle, J.; Astarloa-Pando, G.; Zenarruzabeitia, O.; Borrego, F. Modulating NK cell metabolism for cancer immunotherapy. Semin Hematol 2020, 57 (4), 213. [0074] (15) McCully, J. D.; Levitsky, S.; Del Nido, P. J.; Cowan, D. B. Mitochondrial transplantation for therapeutic use. Clin Transl Med 2016, 5 (1), 16. [0075] (16) Desdin-Mico, G.; Soto-Heredero, G.; Mittelbrunn, M. Mitochondrial activity in T cells. Mitochondrion 2018, 41, 51. [0076] (17) Zhang, Y. Y.; Zhang, Z. M. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020, 17 (8), 807. [0077] (18) S Sarkar, P. S., D Stroopinsky, K Palmer, N Cohen, J Rosenblatt, D Avigan, T Konry. Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets. Biomicrofluidics 2016, 10, 054115. [0078] (19) Agnihotri, S. N.; Ugolini, G. S.; Sullivan, M. R.; Yang, Y.; De Ganzo, A.; Lim, J. W.; Konry, T. Droplet microfluidics for functional temporal analysis and cell recovery on demand using microvalves: application in immunotherapies for cancer. Lab Chip 2022, 22 (17), 3258. [0079] (20) Liu, Z. H.; Sun, Y.; Qi, Z. T.; Cao, L.; Ding, S. Z. Mitochondrial transfer/transplantation: an emerging therapeutic approach for multiple diseases. Cell Biosci 2022, 12 (1). [0080] (21) Mccully, J. D.; del Nido, P. J.; Emani, S. M. Mitochondrial transplantation: the advance to therapeutic application and molecular modulation. Front Cardiovasc Med 2023, 10. [0081] (22) Liu, D. L.; Gao, Y. S.; Liu, J.; Huang, Y. G.; Yin, J. H.; Feng, Y. Y.; Shi, L. J.; Meloni, B. P.; Zhang, C. Q.; Zheng, M. H.et al. Intercellular mitochondrial transfer as a means of tissue revitalization. Signal Transduct Tar 2021, 6 (1). [0082] (23) Ghosh P, V. C., Dey S, Zhang L. Mitochondria Targeting as an Effective Strategy for Cancer Therapy. Int J Mol Sci May 9, 2020, 21(9):3363. [0083] (24) Song, X.; Xu, C. F.; Wu, X. L.; Zhao, X.; Fan, J. P.; Meng, S. F. The potential markers of NK-92 associated to cytotoxicity against K562 cells. Biologicals 2020, 68, 46. [0084] (25) Gonzalez, V. D.; Huang, Y. W.; Delgado-Gonzalez, A.; Chen, S. Y.; Donoso, K.; Sachs, K.; Gentles, A. J.; Allard, G. M.; Kolahi, K. S.; Howitt, B. E.et al. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. Cell Reports 2021, 36 (9). [0085] (26) Klingemann, H.; Boissel, L.; Toneguzzo, F. Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells. Frontiers in Immunology 2016, 7. [0086] (27) Sun J, L. H., Fan L, Yiu T L, Shakoor A, Li G, Lee W Y W, Sun D. High-efficiency quantitative control of mitochondrial transfer based on droplet microfluidics and its application on muscle regeneration. Sci Adv 2022 Aug. 19, 8(33):eabp9245.